Isopogen

Isopogen is a biotechnology company focused on the development of next-generation autologous cell therapies for regenerative medicine. The company utilizes its proprietary Isopogenic platform to isolate and manufacture specific progenitor cell populations designed to treat ischemic and inflammatory diseases. Isopogen's lead programs target critical limb ischemia (CLI) and other vascular conditions where revascularization and tissue repair are needed. Led by industry veterans in the cell therapy space, the company aims to overcome the limitations of traditional stem cell treatments through enhanced cell potency and standardized manufacturing processes. The company's approach leverages the patient's own cells to provide a safe and effective treatment option for chronic conditions.